Safety Study of Bevacizumab (Avastin) With Thoracic Radiation in Non-small Cell Cell Lung Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00531076
(Study terminated due to toxicity)
In spite of the use of radiation combined with conventional chemotherapy, the long-term survival prognosis for most patients with locally advanced non-small cell lung cancer is disappointing. Much effort is currently focussed on exploring new molecular targeted agents that may improve upon survival. The addition of an agent that targets blood vessel formation in tumors, bevacizumab or Avastin, to conventional chemotherapy has been shown to improve survival in metastatic non-small cell lung cancer. Data from animal studies have shown that bevacizumab and related agents also increase tumor cure rates when administered both during and after radiotherapy. This suggests that combined bevacizumab and chemo-radiation may improve survival in local-advanced disease as well. Before such clinical studies can commence, the safety and normal tissue toxicity profile of bevacizumab with thoracic radiotherapy must first be established. In this study, escalating doses of bevacizumab will be administered during radiotherapy, followed by maintenance bevacizumab.
Phase I Study of Concurrent Bevacizumab (Avastin) With Involved-field Thoracic Radiotherapy for Inoperable Non-squamous Non-small Cell Lung Cancer, Followed by Both Concurrent and Maintenance Bevacizumab
Study Start Date
Actual Primary Completion Date
Actual Study Completion Date
Resource links provided by the National Library of Medicine
To establish the safety and tolerability of 2 dose-levels of bevacizumab administered every 3 weeks with concurrent thoracic radiotherapy to 66 Gy,and also maintenance (15 mg/kg) bevacizumab following completion of thoracic radiotherapy [ Time Frame: 1 year ]
Secondary Outcome Measures
Correlate all observed toxicity with dose-volume histograms of irradiated normal organs and explore surrogate tumor end-points that may correlate with the efficacy of combined treatment with anti-VEGF targeted therapy [ Time Frame: 1 year ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
Child, Adult, Senior
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Cytologically or histologically confirmed stages II or III non-squamous NSCLC
No evidence of tumour invading major blood vessels and no active hemoptysis (bright red blood of at least ½ teaspoon) in the 28 days prior to randomization.
No prior systemic therapy for NSCLC. Prior surgery and/or extra-thoracic irradiation is permitted.
Presence of at least one measurable target lesion
Age 18 or greater.
WHO performance status of 0 or 1.
Acceptable pulmonary function as defined by a Fev1 of ≥30% and a DLCO of ≥40% of predicted
Life expectancy of at least 12 weeks.
Adequate hematological, renal and hepatic functions
Absolute neutrophil count >2x109/l.
Platelet count > 100x109/l.
Total bilirubin < 1.5 x UNL
ASAT/ALAT < 2 x UNL
Alkaline phosphatase < 5 x UNL
Creatinine < 130 μmol/L
Creatinine clearance > 60 ml/min; measured or calculated
Urine dipstick for proteinuria < 1+. If urine dipstick is ≥ 1, 24 hour urine must demonstrate < 500 mg of protein in 24 hours.
No pre-existing sensory neurotoxicity grade 2 (CTC)
No active (uncontrolled) infection requiring antibiotics
Mixed tumor types with small cell lung cancer or squamous cell carcinoma
Other serious diseases, such as heart failure, angina pectoris, myocardial infarction within the last 6 months, uncontrolled hypertension
Serious non-healing wound or ulcer.
ASAT and ALAT > 1,5 x UNL
alkaline phosphatase 5 x UNL
Evidence of bleeding diathesis or coagulopathy.
Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be assessed with the patient before registration in the trial.
Participation in other trial with investigational drug or treatment modality.